Ligand Oxidation Activates a Ruthenium(II) Precatalyst for C-H Hydroxylation.
Paul J LauridsenYeon Jung KimDaniel P MarronJie S ZhuRobert M WaymouthJustin Du BoisPublished in: Journal of the American Chemical Society (2024)
A new class of Ru-sulfonamidate precatalysts for sp 3 C-H hydroxylation is described along with a versatile process for assembling unique heteroleptic Ru(II) complexes. The latter has enabled structure-performance studies to identify an optimal precatalyst, 2h , bearing one 4,4'-di- tert -butylbipyridine (dtbpy) and one pyridylsulfonamidate ligand. Single-crystal X-ray analysis confirmed the structure and stereochemistry of this adduct. Catalytic hydroxylation reactions are conveniently performed in an aqueous, biphasic solvent mixture with 1 mol % 2h and ceric ammonium nitrate as the terminal oxidant and deliver oxidized products in yields ranging from 37 to 90%. A comparative mechanistic investigation of 2h against a related homoleptic precatalyst, [Ru(dtbpy) 2 (MeCN) 2 ](OTf) 2 , convincingly establishes that the former generates one or more surprisingly long-lived active species under the reaction conditions, thus accounting for the high turnover numbers. Structure-performance, kinetics, mass spectrometric, and electrochemical analyses reveal that ligand oxidation is a prerequisite for catalyst activation. Our findings sharply contrast a large body of prior art showing that ligand oxidation is detrimental to catalyst function. We expect these results to stimulate future innovations in C-H oxidation research.
Keyphrases
- ionic liquid
- visible light
- hydrogen peroxide
- electron transfer
- room temperature
- energy transfer
- highly efficient
- magnetic resonance imaging
- gold nanoparticles
- escherichia coli
- high resolution
- current status
- hiv infected
- bone mineral density
- metal organic framework
- dna methylation
- cystic fibrosis
- single cell
- staphylococcus aureus
- mass spectrometry
- antiretroviral therapy
- candida albicans
- crystal structure